- Keywords > access to medicines
- Keywords > health priorities
- Keywords > medicines policy
- Keywords > medicines strategy
- Keywords > pharmaceutical gaps
- Keywords > pharmaceutical innovation
- Keywords > pharmaceutical research - priorities
- Keywords > policy - priority issues
- Keywords > priority diseases
- Keywords > priority medicines
(2013; 10 pages)
This is the second report to be issued on Priority Medicines for Europe and the World. It is designed as an update to the original report, which was published in 2004. The original report was initiated during the second half of 2003, when the Government of the Netherlands established the Priority Medicines for Europe and the World Project with the World Health Organization (WHO). The aim was to establish a public-health-based medicines research and development (R&D) agenda and, where necessary, to help bridge the gap between public health needs and the development priorities of the pharmaceutical industry.
In response, the WHO prepared a R&D agenda and methodology based on public health needs and drew up a list of priority medicines a to be proposed for research funding by the European Union (EU) as part of its Seventh Framework Programme (FP7) for 2007 to 2013. In addition to identifying priority medicines needed for EU citizens, the aim was to identify those research needs which are also relevant beyond Europe for countries in economic transition and for developing countries. This "commonality of interest" is an important bridging aspect between the health needs of Europe and the world.